Melphalan- and dexamethasone-based regimens as initial therapy for multiple myeloma.22
| . | MP (n= 109) . | MD (n= 110) . | Dex (n= 109) . | Dex + IFN (n= 101) . |
|---|---|---|---|---|
| Abbreviations: Dex, dexamethasone; IFN, interferon; MD, melphalan and dexamethasone; mos., months; MP, melphalan and prednisone; n, number of patients in each cohort | ||||
| Quality of initial response | ||||
| At least a partial response | 41% | 70% | 40% | 42% |
| Complete response | 1% | 3% | 1% | 1% |
| Long-term outcome measures | ||||
| Median progression-free survival | 21.1 mos. | 22.9 mos. | 12.2 mos. | 15.2 mos. |
| Median overall survival | 34.0 mos. | 39.6 mos. | 33.4 mos. | 32.0 mos. |
| Toxicities | ||||
| Deaths due to progression | 1 (1%) | 0 | 3 (3%) | 9 (9%) |
| Severe pyogenic infection | 12 (11%) | 22 (20%) | 14 (13%) | 11 (11%) |
| Any severe toxicity | 20 (18%) | 36 (33%) | 34 (31%) | 31 (31%) |
| . | MP (n= 109) . | MD (n= 110) . | Dex (n= 109) . | Dex + IFN (n= 101) . |
|---|---|---|---|---|
| Abbreviations: Dex, dexamethasone; IFN, interferon; MD, melphalan and dexamethasone; mos., months; MP, melphalan and prednisone; n, number of patients in each cohort | ||||
| Quality of initial response | ||||
| At least a partial response | 41% | 70% | 40% | 42% |
| Complete response | 1% | 3% | 1% | 1% |
| Long-term outcome measures | ||||
| Median progression-free survival | 21.1 mos. | 22.9 mos. | 12.2 mos. | 15.2 mos. |
| Median overall survival | 34.0 mos. | 39.6 mos. | 33.4 mos. | 32.0 mos. |
| Toxicities | ||||
| Deaths due to progression | 1 (1%) | 0 | 3 (3%) | 9 (9%) |
| Severe pyogenic infection | 12 (11%) | 22 (20%) | 14 (13%) | 11 (11%) |
| Any severe toxicity | 20 (18%) | 36 (33%) | 34 (31%) | 31 (31%) |